secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001558370-25-007878
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech Q1 net loss narrows to $12.7M; Checkpoint acquisition on track
-------------------------------------------------------------------------------

- Consolidated net loss $12.7M ($0.48/sh) vs $17.9M ($1.04/sh) in Q1 2024.
- Cash $91.3M as of March 31, 2025, up $34.0M from Dec 2024; Checkpoint holds $33.0M.
- Emrosi launched in March 2025; first prescriptions filled for inflammatory rosacea lesions.
- Checkpoint to be acquired by Sun Pharma for $4.10/sh plus $0.70 CVR; Fortress expects ~$28M at closing.
- CUTX-101 NDA priority review with PDUFA Sept 30, 2025; Cyprium retains 100% of any PRV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/0001558370-25-007878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer